The trial evaluates not a single drug but rather a general strategy of precision oncology in the
curative setting and provides the basis for future confirmatory biomarker-driven trials.
Eligible patients are identified considering pCR-status and clinical stage estrogen receptor status
grade (CPS-EG)-score following surgery after neoadjuvant therapy. Allocation to the therapy-
arms is conducted by a molecular tumor board based on in depth molecular characterization of
tumors within the COGNITION registry program. Recruitment of adequate patient numbers in
well-defined molecular subgroups is achieved in a multicenter approach.
The study aims to show an overall benefit of the precision medicine approach in high-risk eBC
patients and to allow for secondary exploratory evaluation of each study-arm.
The primary endpoint of the study is invasive Disease-Free Survival (IDFS) after 4 years
measured from surgery to local or distant relapse or death. The sample size of the entire trial is
240 eligible patients.
The trial evaluates not a single drug but rather a general strategy of precision oncology in the
curative setting and provides the basis for future confirmatory biomarker-driven trials.
Eligible patients are identified considering pCR-status and clinical stage estrogen receptor status
grade (CPS-EG)-score following surgery after neoadjuvant therapy. Allocation to the therapy-
arms is conducted by a molecular tumor board based on in depth molecular characterization of
tumors within the COGNITION registry program. Recruitment of adequate patient numbers in
well-defined molecular subgroups is achieved in a multicenter approach.
The study aims to show an overall benefit of the precision medicine approach in high-risk eBC
patients and to allow for secondary exploratory evaluation of each study-arm.
The primary endpoint of the study is invasive Disease-Free Survival (IDFS) after 4 years
measured from surgery to local or distant relapse or death. The sample size of the entire trial is
240 eligible patients.
